Patients in Germany who suffer from allergy to grass pollen will now benefit from a suitable vaccine against it. The newly introduced, tablet based vaccine named Grazax® is being marketed by ALK-Abelló, a public limited company focusing on allergy treatment.
Allergy from grass pollen prominently disrupts quality of life affecting concentration at work or school dampening social interaction severely .Statistics reveal that over 45 million Europeans suffer from this allergy which leads to allergic rhinitis(hay fever) or allergic asthma.
The CEO of ALK-Abelló informed media that Grazax® is the result of years of dedicated research. Since the immunotherapy vaccine is formulated in a tablet form, it is feasible and convenient to patients for treatment at home.Grazax® is to be used as a single dose daily .The company has informed that optimum benefits are achieved if the tablets are taken about 8 weeks prior to onset of the season when grass pollen becomes rampant.
82% of patients, who underwent treatment for grass pollen allergy using Grazax®, reported a definite sense of well being. Previously they had never received any treatment whatsoever.
The company officials have also announced that this vaccine will soon be introduced to other European nations as well, where the company has subsidiary units.